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Abstract
The Ini1 subunit of the SWI/SNF chromatin remodeling
complex suppresses formation of malignant rhabdoid tumors
in humans and mice. Transduction of Ini1 into Ini1-deficient
tumor-derived cell lines has indicated that Ini1 arrests cell
growth, controls chromosomal ploidy, and suppresses tumor-
igenesis by regulating components of the retinoblastoma (Rb)
signaling pathway. Furthermore, conditional inactivation of
Ini1 in mouse fibroblasts alters the expression of various Rb-
E2F-regulated genes, indicating that endogenous Ini1 levels
may control Rb signaling in cells. We have reported previously
that loss of one allele of Ini1 in mouse fibroblasts results only
in a 15% to 20% reduction in total Ini1 mRNA levels due to
transcriptional compensation by the remaining Ini1 allele.
Here, we examine the effects of Ini1 haploinsufficiency on cell
growth and immortalization in mouse embryonic fibroblasts.
In addition, we examine pituitary tumorigenesis in Rb-Ini1
compound heterozygous mice. Our results reveal that hetero-
zygosity for Ini1 up-regulates cell growth and immortalization
and that exogenous Ini1 down-regulates the growth of
primary cells in a Rb-dependent manner. Furthermore, loss
of Ini1 is redundant with loss of Rb function in the formation
of pituitary tumors in Rb heterozygous mice and leads to the
formation of large, atypical Rb+/ tumor cells lacking
adrenocorticotropic hormone expression. These results con-
firm in vivo the relationship between Rb and Ini1 in tumor
suppression and indicate that Ini1 plays a role in maintaining
the morphologic and functional differentiation of cortico-
trophic cells. (Cancer Res 2006; 66(16): 8076-82)
Introduction
SWI/SNF chromatin remodeling complexes hydrolyze ATP to
alter nucleosome-DNA contacts to activate or repress eukaryotic
gene expression (reviewed in refs. 1, 2). The subunit composition
of SWI/SNF complexes varies among cell types; however, all
human SWI/SNF complexes include either the catalytic ATPase
subunit BRM (Brahma) or BRG1 (Brahma-related gene 1), as well as
Ini1 (3, 4). The Ini1 subunit (also known as Snf5) was originally
isolated as a cellular host protein that binds specifically to HIV-1
integrase and as a human homologue to the yeast Snf5 component
of yeast SWI/SNF complex (5, 6).
Chromosomal abnormalities at the Ini1 locus have linked Ini1
mutation with early childhood cancers. Known broadly as rhabdoid
predisposition syndrome, these cancers include atypical teratoid
and rhabdoid tumors of the central nervous system and malignant
rhabdoid tumors (MRT). Germ-line mutations in Ini1 have been
detected in MRT of the kidney and brain, with subsequent deletion
or mutation of the wild-type (WT) Ini1 allele in these tumors (7).
Bialleleic Ini1 mutations have also been detected in sporadic renal
rhabdoid tumors, choroid plexus carcinomas, medulloblastomas,
and central primitive neuroectodermal tumors (8–10). The link
between Ini1 mutation and cancer and the loss of heterozygosity
(LOH) for Ini1 observed in human familial MRT strongly suggests
that Ini1 functions to suppress tumorigenesis.
The tumor-suppressing properties of Ini1 were confirmed by
studies of mice bearing mutations in Ini1 . Embryos homozygous
for disruption of Ini1 (Ini1+/) fail to develop beyond the peri-
implantation stage of gestation (11, 12). Mice haploinsufficient for
Ini1 (Ini1+/) develop normally, but approximately a quarter of
these mice will develop rhabdoid tumors and undifferentiated
sarcomas primarily on the head and neck, many of which are highly
aggressive and metastatic (11–13). Further analysis indicated that
tumor tissues showed loss of the remaining Ini1 locus or were
deficient for Ini1 protein, confirming that the tumors underwent
LOH for Ini1 (11, 12). More recently, transient inactivation of Ini1
using a reversible conditional Ini1 allele in mice led to rapid bone
marrow failure and death of the mice, whereas sporadic
inactivation of Ini1 in hematopoietic tissues and in other organs
resulted in an extremely rapid onset of CD8+ lymphomas and
rhabdoid tumors in all mice (14).
Reintroduction of Ini1 into Ini1-deficient human tumor cell lines
induces a G1 arrest in these cells, a characteristic flat cell forma-
tion, and, in some cases, cell senescence or apoptosis (15–19). Ini1-
deficient tumor cell lines also exhibit chromosomal instability and
polyploidy, both of which can be restored to more normal
conditions by transduction of Ini1 (20). Recent work has begun
to investigate the underlying mechanisms of Ini1-mediated effects
on cell growth and tumor suppression. The SWI/SNF ATPase
subunits BRG1 and BRM are implicated in control of cell growth
and proliferation through their direct interaction with the retino-
blastoma (Rb) tumor suppressor protein (21–24). Rb functions as a
key regulator of the G1-S transition during cell cycling by binding
and inhibiting the activity of E2F transcription factors. Phosphor-
ylation of Rb by cyclin-dependent kinases (CDK) interrupts Rb-E2F
interactions, leading to E2F-induced expression of genes involved
in DNA replication and progression of the cell cycle into S phase.
The link between SWI/SNF ATPases and Rb has promoted investi-
gations into the effects of Ini1 loss on the Rb signaling pathway.
Induction of Rb signaling was found to restore the G1 arrest in Ini1-
deficient cells, suggesting that Ini1 acts upstream of Rb in regula-
ting the G1 checkpoint (16, 18). In support of this hypothesis,
reintroduction of Ini1 into MRT cells was reported to activate the
CDK inhibitor p16INK4a (25) and to induce senescence in cultured
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rhabdoid cells by binding directly to the p16INK4a and p21WAF/CIP
promoters and up-regulating the expression of these CDK inhib-
itors (26). In addition, exogenous Ini1 induces HDAC-dependent
repression of the cyclin D1 promoter (17), and RNA interference
inhibition of cyclin D1 activity was sufficient to restore a G1 arrest
and apoptosis in Ini1-deficient MRT cells (26). Finally, gene
expression profiling indicates that Ini1 activates a mitotic
checkpoint and ploidy control through regulation of E2F target
genes (20).
These tumor cell–based studies suggest that Ini1 functions by
altering CDK phosphorylation of the Rb tumor suppressor. Studies
in Drosophila also implicate the Ini1 homologue Snr1 in controlling
cell growth via the Rb-E2F pathway (27, 28). However, less evidence
is available about the effects of Ini1 loss in normal mammalian
cells. Very recently, Ini1 was conditionally deleted in mouse
embryonic fibroblasts (MEF) by use of the Cre-lox system. In one
report, loss of Ini1 led to aberrant regulation of certain E2F target
genes whose expression levels are also altered in MRT cells. In
addition, inactivation of Ini1 induced a G2 cell cycle arrest,
polyploidy, and apoptosis, with concomitant increases in levels of
p53 and p21 (29). However, in another report, inactivation of Ini1
impaired cell proliferation and survival and induced p53 levels
without affecting E2F-responsive genes (30). These data suggest
that Ini1 loss may perturb both Rb and p53 tumor suppression
pathways. Conditional inactivation of either Rb or p16INK4a did not
alter the rate of tumorigenesis in mice, in which Ini1 was also
conditionally inactivated by induction of Cre expression from an
MX1-Cre transgene (29), whereas coinactivation of both Ini1 and
p53 led to a dramatic increase in the rate of tumor onset (29, 30).
Therefore, apparently, mutation of Rb, but not p53, might be
redundant with Ini1 loss of function in vivo .
We have generated previously Ini1-heterozygous mice and MEFs
and observed that the Ini1 levels in these Ini1-haploinsufficient
cells are similar to WT Ini1 levels due to an increase in the activity
of the remaining Ini1 promoter (12, 31). However, this transcrip-
tional compensation for loss of one allele of Ini1 is not complete
and results in a 15% to 20% reduction in total Ini1 levels in the Ini1-
heterozygous cells. Thus, individuals heterozygous for Ini1 may be
susceptible to the consequences of reduced Ini1 levels. To better
understand the functional relationship between Ini1 and the Rb
tumor suppressor and to determine if haploinsufficiency of Ini1 is
sufficient to alter cell growth, we examined the growth character-
istics of Ini1-heterozygous MEFs. Our results indicate that haplo-
insufficiency of Ini1 increases the rate of cell proliferation and cell
immortalization and that Ini1 requires functional Rb to induce a
senescent-like phenotype in primary cells. Moreover, mice hetero-
zygous for Rb or for both Rb and Ini1 form highly penetrant
pituitary tumors at similar rates. Although adrenocorticotropic
hormone (ACTH)–positive tumor cells displaying LOH for the
remaining WT Rb allele were present in tumors from both cohorts
of mice, large atypical tumor cells lacking ACTH expression were
also readily detected solely in pituitary tumors in the Rb+/, Ini1+/
mice. Laser capture microdissection (LCM) revealed that the small,
ACTH-positive cells underwent LOH for the WT Rb allele while
retaining heterozygosity for Ini1, whereas the large atypical tumor
cells underwent LOH for Ini1 but not for Rb. These findings
indicate that Ini1 and Rb have redundant functions in suppressing
pituitary tumorigenesis in Rb-heterozygous mice and that Ini1 is
important for maintaining the morphologic and functional dif-
ferentiation of normal corticotropic cells as well as those under-
going neoplastic transformation.
Materials and Methods
Cells and mice. Ini1-heterozygous mice and Rb-heterozygous mice have
been described previously (12, 32). MEFs were generated from E12 to E14
embryos as described (33). Genomic DNA was prepared from the hind limb
of each embryo for PCR analysis to identify the genotype of the resulting
fibroblast line. All studies were initiated using low-passage embryonic
fibroblasts (passages 2-4). Ini1+/, Rb+/, and Ini1+/, Rb+/ mice were
maintained on a C57Bl/6129 genetic background. All mice were
maintained and used in accordance with the University of Massachusetts
Animal Care and Use Committee.
Cell studies. To determine the rates of cell proliferation, three different
lines of WT MEF or Ini1-heterozygous MEFs were plated at 5  105 cells per
10-cm dish in MEF media (DMEM, with 10% fetal bovine serum, 0.37%
sodium bicarbonate, penicillin, and streptomycin). Triplicate plates of cells
for each line were harvested and counted at various times following initial
plating using a Z1 Coulter Particle Counter (Beckman Coulter, Miami, FL).
A 3T9 assay was done as described (34) to examine the rate of spontaneous
immortalization of WT MEF and Ini1-heterozygous MEFs. Briefly, 3  106
cells were plated into MEF media in 10-cm dish every 3 days. A total of
three plates (9  106 cells) were maintained for two separate lines of
fibroblasts for each genotype. Triplicate plates for each line were trypsinized
and mixed before counting and replating. Recombinant Ini1 retrovirus
was generated as described previously (31) and used to transduce Ini1 into
WTand Rb-null MEFs. Cells were plated onto 10-cm dishes in MEFmedia at
5  105 per plate and infected with either an Ini1-flag recombinant
retrovirus or an empty vector recombinant virus for 24 hours in the pre-
sence of polybrene. Infected cells were transiently selected in blasticidin
(10 Ag/mL) for 60 hours to identify cells transduced by the recombinant
Ini1 virus, harvested by trypsinization, and counted. Triplicate platings of
transduced cells for each genotype were replated at a density of 4  104 cells
per 10-cm dish, and plates were harvested at various time points following
initial plating and counted using a Z1 Coulter Particle Counter.
Reverse transcription-PCR to detect Ini1 transcripts. Reverse
transcription-PCR (RT-PCR) was done on reverse-transcribed total RNA
isolated from MEFs infected with either pBABE-flag-Ini1 or pBABE-no
insert (31). The primers for the flag-Ini1 cDNA were 5¶-GTCACCACCATCG-
CATACAG-3¶ (F922) and 5¶-TCATTATTTGTCATCGTCGTCCTT-3¶ (R1188).
The primers for the 36B4 control cDNA were 5¶-CAGGCCCTGCACTC-
TCGCTTTCTG-3¶ (F699) and 5¶-TTGGTTGCTTTGGCGGGATTAGTC-3¶
(R1023).
Western analysis. Protein was extracted from 3T9 cells at various
passages and quantified by Bradford analysis, and 50 Ag of each sample
were used for Western analysis with an Ini1 antibody as described (12).
Tumor assays. Ini1-heterozygous mice were crossed with Rb heterozy-
gous mice to establish a cohort of Rb-Ini1 compound heterozygous mice.
Tumor assays were done using these mice and Rb heterozygous mice. Mice
were inspected every other day for morbidity or tumor formation.
Necropsies were done and tumors were harvested and fixed in 10%
buffered formalin phosphate and then processed for paraffin embedding
and sectioning using standard methods. Sections were mounted on a glass
slide and stained with H&E. Sections of adenomas and normal pituitaries
from WT mice were also immunostained for ACTH. Before LCM, cover-
slipped, H&E-stained, and ACTH-immunostained sections were studied
microscopically. Areas of interest were then identified in replicate
deparaffinized, noncovered sections, and LCM was done using an Arcturus
(Mountain View, CA) Pixcell 2 instrument.
Genotyping of tumor samples. Following microdissection of select
areas of tumor slides, the samples were placed into a small Eppendorf
tube and genotyped by PCR for Ini1 and Rb status as described previously
(12, 32).
Results
Increased proliferation of Ini1-heretozygous fibroblasts.
Multiple lines of Ini1+/ MEFs or WT MEFs were generated by
standard methods from E13.5 embryos isolated from pregnant
Ini1 Alters Rb Signaling In vivo
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Ini1+/ female mice intercrossed with WT male mice. Three
separate lines of Ini1+/ or WT MEFs were harvested, plated, and
counted at various times after initial plating to characterize the
growth rate of these early-passage fibroblasts. The results indicate
that Ini1+/ primary fibroblasts show an increase in their rate of
proliferation relative to WT fibroblasts (Fig. 1A). This assay was
repeated twice with similar results.
Cell immortalization studies. To explore the effects of Ini1
haploinsufficiency on cell immortalization, we did a 3T9 assay on
two lines each of MEFs that were either WT or heterozygous for
Ini1 (Fig. 1B). WT MEFs failed to immortalize during the course of
this 3T9 assay, whereas MEFs that were Ini1+/ underwent rapid
spontaneous immortalization by the fifth passage. Western analysis
of Ini1+/ MEFs at various passages during the 3T9 assay revealed
that these cells did not require Ini1 LOH to immortalize, as Ini1
expression was detected throughout various time points in Ini1+/
cells during the course of the 3T9 assay, including as late as passage
30 (Fig. 1C).
Cell transduction studies. Forced overexpression of Ini1 in
MRT cells induces a flattened cell morphology and reduced cell
growth, and several reports have implicated involvement of the
Rb signaling pathway in Ini1-induced senescence (19, 26). To
document the role of Rb in primary cells in Ini1-mediated cell
senescence, we infected multiple lines of WT MEFs or MEFs
derived from Rb-null embryos with a recombinant retrovirus
that encodes a flag-tagged Ini1 and a blasticidin drug selec-
tion marker. Following infection and transient selection in
blasticidin, the cells were harvested and plated in 10-cm dishes,
and a proliferation assay was done using the transduced cells (35).
WT MEFs infected with an empty vector virus continued to
proliferate slowly throughout the assay (Fig. 2A). In contrast,
WT MEFs transduced with virus encoding Ini1 assumed a flattened
cell appearance and divided only minimally postinfection. As
expected, Rb-null MEFs infected with an empty vector proliferated
far faster than WT MEFs infected with empty vector virus.
Interestingly, transduction of Ini1 failed to alter the morphology
or growth characteristics of Rb-null MEFs, indicating that the
replicative senescence-like effects of Ini1 expression are Rb-
dependent. RT-PCR analysis of total RNA harvested from mock
or Ini1-tranduced cells confirmed expression of exogenous, flag-
tagged Ini1 in Rb and WT MEFs infected with the recombinant
Ini1 virus (Fig. 2B).
Tumorigenesis in Ini1-Rb compound heterozygous mice. We
have described previously Ini1 as a tumor suppressor in mice (12).
To explore further genetic interactions between the Ini1 and Rb
tumor suppressors in vivo , we generated Rb-Ini1 compound
heterozygous mice by breeding Ini1+/ mice with Rb+/ mice.
Rb-null mice develop normally until E14 but fail to develop
thereafter due to massive cell death in the nervous system and
defects in erythropoesis (32, 36, 37). Rb+/ mice are viable and
appear normal but form foci of atypical melanotroph precursor
cells in the intermediate lobe of the pituitary as early as 30 days
after birth (38). Eventually, adenocarcinomas develop in the
anterior pituitary lobe as do medullary thyroid adenomas and
neuroendocrine tumors (38–41). Ultimately, 100% of Rb+/ mice
succumb to pituitary tumors, and LOH for the WT Rb allele is
observed in all late-stage tumors and in some of the microdissected
atypical cells of early proliferates (38, 40).
To determine whether haploinsufficiency for Ini1 alters tumor-
igenesis in Rb heterozygous mice, a cohort of Rb+/, Ini1+/ mice
was generated and analyzed for the formation of spontaneous
tumors. The rate and tissue spectrum of tumor formation in these
compound heterozygous mice was compared with tumorigenesis
in mice heterozygous for either Rb or Ini1. Mice heterozygous for
Figure 1. Haploinsufficiency for Ini1 alters the proliferation and spontaneous immortalization of MEFs. A, analysis of the growth rate of (WT) MEFs and
Ini1-heterozygous MEFs reveals that Ini1 haploinsufficiency induces a faster rate of proliferation in cells. B, immortalization of WT MEFs and Ini1-heterozygous
MEFs. WT MEFs failed to immortalize following a 3T9 protocol to assess spontaneous immortalization, whereas cells haploinsufficient for Ini1 readily immortalized.
C, Western analysis of Ini1 protein in the immortalized Ini1+/ cells at various passage numbers reveals that the Ini1-heterozygous cells retain Ini1 expression.
The Ini1 antibody detects two Ini1 proteins generated through differential splicing of the Ini1 transcript (50).
Cancer Research
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both Rb and Ini1 developed pituitary tumors at a rate and
penetrance indistinguishable from tumor formation in Rb+/ mice
(Fig. 3). The spectrum of tumors observed in Rb+/ mice WT or
heterozygous for Ini1 was also quite similar; except for one
compound heterozygous mouse that developed thymic lymphoma,
only pituitary tumorigenesis was detected Rb+/mice and in Rb+/,
Ini1+/ mice. Interestingly, no rhabdoid-like tumors or poorly
differentiated sarcomas were observed on the head and neck of
Ini1+/, Rb+/ mice during this assay, although f20% of Ini1+/
mice present with these cancers in the same time frame. Thus,
haploinsufficiency for Ini1 does not alter the onset, penetrance, or
spectrum of tumor formation in Rb+/ mice. Furthermore, deletion
of WT Rb or WT Ini1 did not rescue the embryonic lethality of
either Ini1-null mice or Rb-null mice, respectively, because
intercrossing of the compound heterozygous mice did not cause
Ini1-null or Rb-null mice.
Histologic features and genotype of tumors arising in Rb+/,
Ini1+/ mice. The size of pituitary tumors in the Rb-Ini1
compound heterozygous mice ranged from 4 to 7 mm in diameter,
similar to what was observed in pituitary tumors arising in Rb+/
mice in this and in other published studies (39, 42).
Pituitary tumors in Rb+/ mice contained a uniform popula-
tion of cells that morphologically resemble corticotrophic cells
normally present in the intermediate and anterior pituitary lobes.
Analysis of tumor sections revealed that the tumor cells in the
pituitary of Rb heterozygous mice consistently immunostained
strongly for ACTH (Fig. 4A). ACTH is a marker for anterior lobe
corticotrope pituitary cells (Fig. 4B) and is expressed in both
benign and malignant pituitary tumors that arise in Rb+/mice (43).
Tumors from Rb+/, Ini1+/ compound mice also exhibited a
similar morphology and robust ACTH staining pattern. However,
large ACTH-negative cells could also be found in more than half of
the Rb+/, Ini1+/ tumors. These atypical cells were usually poly-
gonal, displayed large round vesicular nuclei, and abundant
amphophilic cytoplasm and present in aggregates scattered
throughout the tumor tissue (Fig. 4C-D). Notably, these large
ACTH-negative cells were observed only in pituitary tumors that
arose in the Rb-Ini1 compound heterozygous mice.
Laser capture microscopy was done on sections of several
different pituitary tumors that arose in Rb-heterozygous mice to
genotype the small typical cells present in the tumor mass (Fig. 5A).
In each case, the cells had undergone LOH for the WT Rb allele in
the tumor (Fig. 5B), consistent with previous reports on pituitary
tumorigenesis in Rb-heterozygous mice (38, 40). The presence of
atypical cells in the compound heterozygous tumors prompted us
to examine whether the cells bearing these unique features had
undergone LOH for the WT Ini1 allele. Cells from regions of tumors
that contained the large, ACTH-negative cells were collected by
laser capture microscopy, as were small cells from regions bearing
the classic features of typical Rb+/ pituitary adenomas. In three of
four Rb+/, Ini1+/ tumors examined, the large atypical cells
displayed loss of the WT Ini1 allele. In marked contrast, the WT
Ini1 allele was retained in the smaller cells from the same tumors
(Fig. 5C and D). Previous studies of pituitary adenomas in Rb+/
mice showed for the WT Rb allele in both earliest detected atypical
proliferates and all pituitary adenocarcinomas. However, genotyp-
ing of the large, ACTH-negative cells present in the pituitary
tumors of Rb-Ini1 compound heterozygous mice in this present
study revealed that the WT Rb allele was retained in the large
tumor cells. Instead, these atypical cells had undergone LOH for
the functional Ini1 allele.
Discussion
Evidence in the literature indicates that the Ini1 tumor
suppressor plays a role in regulating cell growth and chromosomal
Figure 3. Interaction between Rb and Ini1 in tumor suppression. A Kaplan-
Meier plot of the frequency of spontaneous tumorigenesis in cohorts of Ini1+/
(Ini1 het ), Rb+/ (Rb het ), or Rb+/, Ini1+/ (Rb/Ini1 het ) mice (n = 25). Rb+/ and
Rb+/, Ini1+/ mice succumbed to pituitary tumors at the same rate.
Figure 2. Overexpression of Ini1 in MEFs induces cell growth arrest.
A, retroviral-mediated transduction of Ini1 into WT MEFs retards the growth of
these cells and induces a senescence-like state. However, transduction of
Ini1 into Rb-null MEFs does not alter the growth of these cells, showing that
effects of Ini1 overexpression on cell growth are Rb-dependent. B, transduced
Ini1 (flag-tag) expression is detected by RT-PCR using primers to Ini1 and
the flag sequences in WT and Rb+/ MEFs infected with Ini1 recombinant
retrovirus. RT-PCR against 36B4 cDNA was done as a control for RNA quality.
Ini1 Alters Rb Signaling In vivo
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ploidy by regulating components of the Rb signaling pathway,
including CDK inhibitors and/or cyclin D1 (reviewed in ref. 44).
However, most of these studies were done using forced
overexpression of Ini1 into Ini1-deficient malignant rhabdoid
tumor-derived cell lines. More recently, analysis of tumorige-
nesis in mice revealed tumorigenesis induced by deletion of
Ini1 was not altered on codeletion of either Rb or p16ink4, whereas
loss of cyclin D1 activity inhibited tumorigenesis in Ini1-null
mice (29, 45). These findings suggest that the Rb and Ini1 may
possess redundant tumor-suppressing capabilities. Less data
are available about the role of Ini1 in regulating p53 functions
in cells or mice. Conditional deletion of Ini1 was reported to
increase p53 activity in MEFs, suggesting that Ini1 negatively
regulates p53 functions (29, 30). However, deletion of p53 also
dramatically increased the onset of tumor formation fol-
lowing conditional deletion of Ini1 in mice in these studies,
suggesting that Ini1 and p53 may also cooperate in preventing
oncogenesis.
In this study, we have examined the growth characteristics
of Ini1-haploinsufficient MEFs. The results reveal that loss of
one allele of Ini1 increases the rate of cell proliferation, in keep-
ing with the findings of earlier reports, indicating that Ini1
overexpression negatively regulates cell growth (15–19, 31). These
data also indicate that haploinsufficiency of Ini1 can have
functional ramifications on cell proliferation despite the com-
pensatory effects of increased Ini1 expression from the remain-
ing WT Ini1 allele (31). Spontaneous immortalization of Ini1+/
MEFs was also readily achieved in the 3T9 assay. Interestingly,
cells haploinsufficient for Ini1 spontaneously immortalized without
undergoing loss for Ini1, whereas WT cells failed to immortalize
in this assay, again suggesting that primary cells haploinsufficient
for Ini1 have altered growth characteristics.
To explore the Rb-mediated effects of Ini1 in primary cells, we
transduced Ini1 expression into WT and Rb-deficient MEFs.
Expression of exogenous Ini1 in MEFs induced a cell growth arrest
and flat cell morphology, similar to previous findings of the effect
of forced Ini1 expression in MRT cells (15–19). However, Ini1
transduction had no effect on MEFs lacking functional Rb,
indicating that the senescence-inducing properties of Ini1 are Rb-
dependent in these cells.
The development of pituitary adenomas in Rb+/ mice was
accelerated on crossing the Rb-mutant mice with mice deficient
for p27, p53, or p19ARF tumor suppressors (46–48). However,
LOH of the WT Rb allele was observed in all tumors arising in
these studies. To explore further the relationship between Rb
and the Ini1 tumor suppressor in vivo , we generated Ini1-Rb
compound heterozygous mice and compared tumor formation
in these mice with tumorigenesis in Ini1+/ or Rb+/ mice. The
rate and spectrum of tumor formation in Rb-heterozygous mice
was unaltered by the presence of one or two copies of func-
tional Ini1. Analysis of the genotypes of tumor cells determined
that most tumor cells displayed LOH for the WT Rb allele as
expected. However, not all pituitary adenoma cells lost func-
tional Rb: the large atypical cells that were ACTH negative retained
the WT Rb allele and displayed LOH for the functional Ini1 allele.
These results indicate that loss of Rb or Ini1 is redundant in
Figure 4. Identifying corticotropic tumor cells by immunostaining for ACTH. Although pituitary tumors formed in both cohorts of Rb+/ mice and in Rb-Ini1+/
mice, differences were seen in ACTH expression in the tumors. A, representative ACTH immunostaining of tumor cells in the pituitary of an Rb+/ mouse. All tested
tumors that arose in Rb+/ mice stained highly for ACTH. B, ACTH staining in nontumor (control) pituitary tissue of Rb+/-, Ini1+/- mice. ACTH is expressed in the
intermediate lobe, with scattered foci of ACTH-positive cells in the adjacent anterior pituitary. C and D, non-ACTH cells were readily observed in tumors that formed in
Rb+/, Ini1+/ mice. Non-ACTH staining cells were observed both in clusters within the tumor and in individual cells dispersed throughout the tumor sections.
Cancer Research
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some pituitary tumors in mice, suggesting that these two tumor
suppressors function similarly in preventing this type of cancer.
However, loss of Ini1 in these tumors also seemed to alter the
morphology of the tumor cell, with Ini1-null cells appearing
larger and lacking ACTH expression. Based on these observations,
we hypothesize that loss of Rb or Ini1 occurs early in cells of
the intermediate and anterior pituitary lobes in the Ini1+/. Rb+/
mice and that complete loss of one tumor suppressor elimi-
nates the need for LOH of the other suppressor gene in tumor
formation. Surprisingly, mice haploinsufficient for both Rb and Ini1
failed to form any sarcomas or rhabdoid-like tumors of the head
and neck in contrast to those observed in Ini1+/ mice. Therefore,
although Rb and Ini1 appear redundant in suppressing pituitary
tumorigenesis in these mice, the lack of MRT tumors in the Rb+/,
Ini1+/ mice suggests that Rb is epistatic to Ini1 in tumor
suppression.
The appearance of Ini1-deficient pituitary tumor cells that
were enlarged relative to the Ini1 heterozygous, Rb-deficient
tumor cells is reminiscent of the behavior of proliferating immor-
talized cells that express a dominant-negative version of the Brg1
ATPase. These cells were larger than counterpart cells not
expressing the mutant Brg1, showing increased area of surface
attachment, increased cell volume, and increased levels of proteins
associated with cell adhesion (49). In both studies, the results
suggest that interference with SWI/SNF enzyme function affects
pathways controlling cell size and shape without blocking cell
proliferation. Additional analyses will be needed to identify the
specific genes involved and to address mechanisms by which
chromatin remodeling enzymes affect the physical variables
controlling cell size and shape. We note that these observations
differ from previous documentation of a ‘‘flat cell’’ phenotype when
Ini1 or BRG1 are ectopically expressed in Ini1- or BRG1-deficient
tumor cells (15–19, 21, 22), as these cells are inevitably growth
arrested.
The results of our study indicate that Ini1 regulates Rb functions
in murine primary cells in vitro and in vivo and that Ini1
haploinsufficiency has functional consequences on cell growth.
These results suggest that there might be clinical ramifications to
Ini1 haploinsufficiency in members of MRT families. In addition,
Ini1 seems to have morphologic consequences in pituitary cells and
to regulate ACTH expression. Further analysis of Rb functions in
Ini1+/ and Ini1-null cells and in mice should help elucidate the
precise interplay of these signaling pathways in regulating cell
proliferation and in tumor suppression.
Acknowledgments
Received 4/21/2006; revised 6/8/2006; accepted 6/19/2006.
Grant support: National Institute of Diabetes and Digestive and Kidney Diseases
Program Project grant 5P30DK32520 (core facilities) and NIH grants GM56244 (A.N.
Imbalzano) and CA95216 (S.N. Jones).
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Dr. Michael Slayter of IDEXX Laboratories (Grafton, MA) for assistance in
tumor analysis, Debra Rigor and Judith Gallant for technical assistance, Charlene
Baron for help with article preparation, and Karen Dressler for assistance with ACTH
immunostaining.
Figure 5. Tumors in Rb+/, Ini1+/ mice undergo LOH for either Rb or Ini1. A, typical H&E-stained section of a pituitary tumor that arose in a Rb-heterozygous
mouse. Magnification of the image was either at 10 or 40. B, single cells were isolated from unstained tumor sections by laser capture microscopy, and DNA
was isolated and used in PCRs to genotype the tumor. Two tumors that arose in Rb+/ mice displaying LOH for the WT Rb allele are shown, along with a negative
control and a positive control (cells harvested from WT pituitary tissue). C, representative H&E-stained section of pituitary tumors that arose in Ini1/Rb compound
heterozygous mouse. Magnification of the image was either at 10 or 40. Arrows, large, atypical tumor cell morphology that fail to express ACTH. D, examples of the
genotyping of the atypical cells (large cells) and typical (small cells) found in the pituitary tumors of compound heterozygous mice. The large, ACTH-negative cells
retained the WT Rb allele and underwent LOH for Ini1, whereas the smaller cells that stain for ACTH in the tumor mass also retain the functional Ini1 allele and display
LOH for Rb.
Ini1 Alters Rb Signaling In vivo
www.aacrjournals.org 8081 Cancer Res 2006; 66: (16). August 15, 2006
References
1. Smith CL, Peterson CL. ATP-dependent chromatin
remodeling. Curr Top Dev Biol 2005;65:115–48.
2. Sif S. ATP-dependent nucleosome remodeling com-
plexes: enzymes tailored to deal with chromatin. J Cell
Biochem 2004;91:1087–98.
3. Kwon H, Imbalzano AN, Khavari PA, et al. Nucleosome
disruption and enhancement of activator binding by a
human SWI/SNF complex. Nature 1994;370:477–81.
4. Wang W, Cote J, Xue Y, et al. Purification and
biochemical heterogeneity of the mammalian SWI-SNF
complex. EMBO J 1996;15:5370–82.
5. Kalpana GV, Marmon S, Wang W, et al. Binding and
stimulation of HIV-1 integrase by a human homolog of
yeast transcription factor SNF5. Science 1994;266:2002–6.
6. Muchardt C, Sardet C, Bourachot B, et al. A human
protein with homology to Saccharomyces cerevisiae
SNF5 interacts with the potential helicase hbrm. Nucleic
Acids Res 1995;23:1127–32.
7. Versteege I, Sevenet N, Lange J, et al. Truncating
mutations of hSNF5/INI1 in aggressive paediatric
cancer. Nature 1998;394:203–6.
8. Rousseau-Merck MF, Versteege I, Legrand I, et al.
hSNF5/INI1 inactivation is mainly associated with
homozygous deletions and mitotic recombinations in
rhabdoid tumors. Cancer Res 1999;59:3152–6.
9. Sevenet N, Sheridan E, Amram D, et al. Constitutional
mutations of the hSNF5/INI1 gene predispose to a
variety of cancers. Am J Hum Genet 1999;65:1342–8.
10. Biegel JA, Kalpana G, Knudsen ES, et al. The role of
INI1 and the SWI/SNF complex in the development of
rhabdoid tumors: meeting summary from the workshop
on childhood atypical teratoid/rhabdoid tumors. Cancer
Res 2002;62:323–8.
11. Klochendler-Yeivin A, Fiette L, Barra J, et al. The
murine SNF5/INI1 chromatin remodeling factor is
essential for embryonic development and tumor sup-
pression. EMBO Rep 2000;1:500–6.
12. Guidi CJ, Sands AT, Zambrowicz BP, et al. Disruption
of Ini1 leads to peri-implantation lethality and tumor-
igenesis in mice. Mol Cell Biol 2001;21:3598–603.
13. Roberts CW, Galusha SA, McMenamin ME, et al.
Haploinsufficiency of Snf5 (integrase interactor 1)
predisposes to malignant rhabdoid tumors in mice.
Proc Natl Acad Sci U S A 2000;97:13796–800.
14. Roberts CW, Leroux MM, Fleming MD, et al. Highly
penetrant, rapid tumorigenesis through conditional
inversion of the tumor suppressor gene Snf5. Cancer
Cell 2002;2:415–25.
15. Ae K, Kobayashi N, Sakuma R, et al. Chromatin
remodeling factor encoded by ini1 induces G1 arrest
and apoptosis in ini1-deficient cells. Oncogene 2002;21:
3112–20.
16. Versteege I, Medjkane S, Rouillard D, et al. A key role
of the hSNF5/INI1 tumour suppressor in the control of
the G1-S transition of the cell cycle. Oncogene 2002;21:
6403–12.
17. Zhang ZK, Davies KP, Allen J, et al. Cell cycle arrest
and repression of cyclin D1 transcription by INI1/
hSNF5. Mol Cell Biol 2002;22:5975–88.
18. Betz BL, Strobeck MW, Reisman DN, et al. Re-
expression of hSNF5/INI1/BAF47 in pediatric tumor
cells leads to G1 arrest associated with induction of
p16ink4a and activation of RB. Oncogene 2002;21:
5193–203.
19. Reincke BS, Rosson GB, Oswald BW, et al. INI1
expression induces cell cycle arrest and markers of
senescence in malignant rhabdoid tumor cells. J Cell
Physiol 2003;194:303–13.
20. Vries RG, Bezrookove V, Zuijderduijn LM, et al.
Cancer-associated mutations in chromatin remodeler
hSNF5 promote chromosomal instability by com-
promising the mitotic checkpoint. Genes Dev 2005;19:
665–70.
21. Dunaief JL, Strober BE, Guha S, et al. The retino-
blastoma protein and BRG1 form a complex and
cooperate to induce cell cycle arrest. Cell 1994;79:
119–30.
22. Strober BE, Dunaief JL, Guha S, et al. Functional
interactions between the hBRM/hBRG1 transcriptional
activators and the pRB family of proteins. Mol Cell Biol
1996;16:1576–83.
23. Zhang HS, Gavin M, Dahiya A, et al. Exit from G1 and
S phase of the cell cycle is regulated by repressor
complexes containing HDAC-Rb-hSWI/SNF and Rb-
hSWI/SNF. Cell 2000;101:79–89.
24. Strobeck MW, Knudsen KE, Fribourg AF, et al. BRG-1
is required for RB-mediated cell cycle arrest. Proc Natl
Acad Sci U S A 2000;97:7748–53.
25. Oruetxebarria I, Venturini F, Kekarainen T, et al.
p16INK4a is required for hSNF5 chromatin remodeler-
induced cellular senescence in malignant rhabdoid
tumor cells. J Biol Chem 2004;279:3807–16.
26. Chai J, Charboneau AL, Betz BL, et al. Loss of the
hSNF5 gene concomitantly inactivates p21CIP/WAF1 and
p16INK4a activity associated with replicative senescence
in A204 rhabdoid tumor cells. Cancer Res 2005;65:
10192–8.
27. Brumby AM, Zraly CB, Horsfield JA, et al. Drosophila
cyclin E interacts with components of the Brahma
complex. EMBO J 2002;21:3377–89.
28. Zraly CB, Marenda DR, Dingwall AK. SNR1 (INI1/
SNF5) mediates important cell growth control functions
of the Drosophila Brahma (SWI/SNF) chromatin remod-
eling complex. Genetics 2004;168:199–214.
29. Isakoff MS, Sansam CG, Tamayo P, et al. Inactivation
of the Snf5 tumor suppressor stimulates cell cycle
progression and cooperates with p53 loss in oncogenic
transformation. Proc Natl Acad Sci U S A 2005;102:
17745–50.
30. Klochendler-Yeivin A, Picarsky E, Yaniv M. Increased
DNA damage sensitivity and apoptosis in cells lacking
the Snf5/Ini1 subunit of the SWI/SNF chromatin
remodeling complex. Mol Cell Biol 2006;26:2661–74.
31. Guidi CJ, Veal TM, Jones SN, et al. Transcriptional
compensation for loss of an allele of the Ini1 tumor
suppressor. J Biol Chem 2004;279:4180–5.
32. Jacks T, Fazeli A, Schmitt EM, et al. Effects of an Rb
mutation in the mouse. Nature 1992;359:295–300.
33. Todaro GJ, Green H. Quantitative studies of the
growth of mouse embryo cells in culture and their
development into established lines. J Cell Biol 1963;17:
299–313.
34. Harvey M, Sands AT, Weiss RS, et al. In vitro growth
characteristics of embryo fibroblasts isolated from p53-
deficient mice. Oncogene 1993;8:2457–67.
35. Steinman HA, Burstein E, Lengner C, et al. An
alternative splice form of Mdm2 induces p53-indepen-
dent cell growth and tumorigenesis. J Biol Chem 2004;
279:4877–86.
36. Lee EY, Chang CY, Hu N, et al. Mice deficient for Rb
are nonviable and show defects in neurogenesis and
haematopoiesis. Nature 1992;359:288–94.
37. Clarke AR, Maandag ER, van Roon M, et al.
Requirement for a functional Rb-1 gene in murine
development. Nature 1992;359:328–30.
38. Nikitin AYu, Lee WH. Early loss of the retinoblastoma
gene is associated with impaired growth inhibitory
innervation during melanotroph carcinogenesis in Rb+/
mice. Genes Dev 1996;10:1870–9.
39. Hu N, Gutsmann A, Herbert DC, et al. Heterozygous
Rb-1 y 20/+mice are predisposed to tumors of the
pituitary gland with a nearly complete penetrance.
Oncogene 1994;9:1021–7.
40. Harrison DJ, Hooper ML, Armstrong JF, et al. Effects
of heterozygosity for the Rb-1t19neo allele in the mouse.
Oncogene 1995;10:1615–20.
41. Williams BO, Schmitt EM, Remington L, et al.
Extensive contribution of Rb-deficient cells to adult
chimeric mice with limited histopathological conse-
quences. EMBO J 1994;13:4251–9.
42. Maandag EC, van der Valk M, Vlaar M, et al.
Developmental rescue of an embryonic-lethal mutation
in the retinoblastoma gene in chimeric mice. EMBO J
1994;13:4260–8.
43. Hinton DR, Hahn JA, Weiss MH, et al. Loss of Rb
expression in an ACTH-secreting pituitary carcinoma.
Cancer Lett 1998;126:209–11.
44. Tsikitis M, Zhang Z, Edelman W, et al. Genetic
ablation of cyclin D1 abrogates genesis of rhabdoid
tumors resulting from Ini1 loss. Proc Natl Acad Sci
U S A 2005;102:12129–34.
45. Imbalzano AN, Jones SN. Snf5 tumor suppressor
couples chromatin remodeling, checkpoint control, and
chromosomal stability. Cancer Cell 2005;7:294–5.
46. Harvey M, Vogel H, Lee EY, et al. Mice deficient in
both p53 and Rb develop tumors primarily of endocrine
origin. Cancer Res 1995;55:1146–51.
47. Park MS, Rosai J, Nguyen HT, et al. p27 and Rb are on
overlapping pathways suppressing tumorigenesis in
mice. Proc Natl Acad Sci U S A 1999;96:6382–7.
48. Tsai KY, MacPherson D, Rubinson DA, et al. ARF
mutation accelerates pituitary tumor development in
Rb+/ mice. Proc Natl Acad Sci U S A 2002;99:16865–70.
49. Hill DA, Chiosea S, Jamaluddin S, et al. Inducible
changes in cell size and attachment area due to
expression of a mutant SWI/SNF chromatin remodeling
enzyme. J Cell Sci 2004;117:5847–54.
50. Bruder CE, Dumanski JP, Kedra D. The mouse
ortholog of the human SMARCB1 gene encodes two
splice forms. Biochem Biophys Res Commun 1999;257:
886–90.
Cancer Research
Cancer Res 2006; 66: (16). August 15, 2006 8082 www.aacrjournals.org
